Metsera
Acquired by Pfizer / NASDAQ: MTSR
Developing next-generation medicines for obesity and metabolic diseases.
Sector
Life SciencesCategory
TherapeuticsLocation
New York, NYInitial Investment
2024
Developing next-generation medicines for obesity and metabolic diseases.
Metsera is a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases. Metsera is advancing a broad portfolio of oral and injectable incretin, non-incretin and combination therapies with potential best-in-class profiles to address multiple therapeutic targets and meet the future needs of a rapidly evolving weight loss treatment landscape. Metsera was acquired by Pfizer in 2025.
“F-Prime shared our purpose and vision of a company serving patients with overweight, obesity and metabolic disease at scale. Our partnership - both before and during the Metsera journey - helped assemble a differentiated portfolio of candidate medicines and build an organization to deliver next generation products in this field.”
Clive Meanwell, Co-founder & Executive Chairman